Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,338.45
(
-0.25%
)
News Focus
News Focus
Post# of 1153
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

surf1944

Send PM Follow Ignore
Followers 468
Posts 26955
Boards Moderated 1
Alias Born 09/11/2006

surf1944

Re: surf1944 post# 696

Tuesday, 09/10/2013 2:54:44 PM

Tuesday, September 10, 2013 2:54:44 PM

Post# of 1153
8:34AM PharmAthene: Theraclone Sciences announces initiation of Phase 2a trial of TCN-202 for the prevention of human cytomegalovirus infection (PIP) 2.10 : Theraclone Sciences announced that it has dosed the first patient in a Phase 2a clinical trial of TCN-202 for the prevention of human cytomegalovirus infection in solid organ transplant recipients. TCN-202 is a recombinant, fully human monoclonal antibody discovered using the Company's proprietary I-STAR platform. On Aug 1, 2013, Theraclone Sciences and PharmAthene announced a definitive merger agreement.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today